{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-109389","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2022-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.281235+00:00","generated_at":"2026-06-23T03:19:31.594280+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Hepion reports $71.7M cash; progressing Phase 2 NASH and upcoming HCC trials","bullets":["Cash and equivalents of $71.7M as of June 30, 2022; 76.2M common shares outstanding.","Rencofilstat Phase 2b ASCEND-NASH (biopsy) and Phase 2 ALTITUDE-NASH (liver function) trials underway.","Upcoming Phase 2a HCC trial for rencofilstat in advanced hepatocellular carcinoma.","AI-POWR platform used to identify responders and companion diagnostic panel.","Rencofilstat shown safe/tolerated in >200 subjects; Phase 2a AMBITION study met primary endpoints."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-109389","json":"https://secwatch.observer/filing/0001104659-22-109389.json","markdown":"https://secwatch.observer/filing/0001104659-22-109389.md","text":"https://secwatch.observer/filing/0001104659-22-109389.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000110465922109389/0001104659-22-109389-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000110465922109389/tm2228403d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T03:19:31.594280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}